NO981392L - Substituerte pyrazolylbenzensulfonamider for anvendelse i veterinµrterapi som antiinflammatorisk middel - Google Patents

Substituerte pyrazolylbenzensulfonamider for anvendelse i veterinµrterapi som antiinflammatorisk middel

Info

Publication number
NO981392L
NO981392L NO981392A NO981392A NO981392L NO 981392 L NO981392 L NO 981392L NO 981392 A NO981392 A NO 981392A NO 981392 A NO981392 A NO 981392A NO 981392 L NO981392 L NO 981392L
Authority
NO
Norway
Prior art keywords
inflammatory agent
veterinary therapy
pyrazolylbenzenesulfonamides
substituted
substituted pyrazolylbenzenesulfonamides
Prior art date
Application number
NO981392A
Other languages
English (en)
Other versions
NO981392D0 (no
NO321157B1 (no
Inventor
Peter C Isakson
John J Talley
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24138015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO981392(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of NO981392D0 publication Critical patent/NO981392D0/no
Publication of NO981392L publication Critical patent/NO981392L/no
Publication of NO321157B1 publication Critical patent/NO321157B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19981392A 1995-09-29 1998-03-27 Anvendelse av substituerte pyrazolylbenzensulfonamider for fremstilling av et antiinflammatorisk middel til bruk innen veterinaermedisin. NO321157B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/536,318 US5756529A (en) 1995-09-29 1995-09-29 Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
PCT/US1996/015538 WO1997011704A1 (en) 1995-09-29 1996-09-27 Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies as antiinflammatory agents

Publications (3)

Publication Number Publication Date
NO981392D0 NO981392D0 (no) 1998-03-27
NO981392L true NO981392L (no) 1998-05-25
NO321157B1 NO321157B1 (no) 2006-03-27

Family

ID=24138015

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981392A NO321157B1 (no) 1995-09-29 1998-03-27 Anvendelse av substituerte pyrazolylbenzensulfonamider for fremstilling av et antiinflammatorisk middel til bruk innen veterinaermedisin.

Country Status (21)

Country Link
US (1) US5756529A (no)
EP (1) EP0854723B1 (no)
JP (1) JPH11514991A (no)
KR (1) KR100498730B1 (no)
CN (1) CN1202828A (no)
AT (1) ATE238058T1 (no)
AU (1) AU718300B2 (no)
BR (1) BR9610974A (no)
CA (1) CA2233620C (no)
CZ (1) CZ297183B6 (no)
DE (1) DE69627683T2 (no)
DK (1) DK0854723T3 (no)
ES (1) ES2197954T3 (no)
IL (1) IL123635A (no)
NO (1) NO321157B1 (no)
NZ (1) NZ320919A (no)
PL (1) PL191934B1 (no)
PT (1) PT854723E (no)
RO (1) RO120408B1 (no)
RU (1) RU2253456C2 (no)
WO (1) WO1997011704A1 (no)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492411B1 (en) * 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
EP0828718A1 (en) * 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
TNSN99111A1 (fr) * 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
NZ513965A (en) * 1999-03-10 2004-04-30 G Method and composition for administering a cyclooxygenase-2 inhibitor
ATE361748T1 (de) 1999-06-16 2007-06-15 Univ Temple 1-(4-sulfamylphenyl)-3-trifluormethyl-5-aryl-2- pyrazoline als cyclooxygenase-2 inhibitoren
DE60018792T2 (de) * 1999-12-03 2006-01-26 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen
EP1104758B1 (en) * 1999-12-03 2003-07-23 Pfizer Products Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
TR200302047T4 (tr) * 1999-12-03 2004-01-21 Pfizer Products Inc. Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri.
ATE234299T1 (de) 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
YU57801A (sh) * 1999-12-08 2005-07-19 Pharmacia Corporation Polimorfni kristalni oblici celecoxib-a
PT1239857E (pt) * 1999-12-22 2006-07-31 Pharmacia Corp Composicoes de libertacao dupla de um inibidor de ciclo-oxigenase-2
EP1274424A4 (en) * 2000-04-12 2003-09-17 Smithkline Beecham Corp CONNECTIONS AND PROCEDURE
US20020107250A1 (en) * 2000-04-18 2002-08-08 Madhusudan Hariharan Rapid-onset formulation of a selective cyclooxygenase-2 inhibitor
WO2001081333A2 (en) * 2000-04-25 2001-11-01 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
DE60204823T2 (de) 2001-07-05 2005-12-29 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonyl Pyrazole als entzündungshemmende/analgetische Mittel
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP2005506983A (ja) 2001-09-19 2005-03-10 ファルマシア・コーポレーション 炎症の治療のための置換ピラゾリル化合物
WO2003024936A1 (en) * 2001-09-19 2003-03-27 Pharmacia Corporation Substituted pyrazolo compounds for the treatment of inflammation
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037330A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
JP2005515171A (ja) 2001-11-02 2005-05-26 ファイザー・プロダクツ・インク ５−ヘテロ原子含有ピラゾールの効率的な合成法
WO2003037335A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 5-heteroatom-substituted pyrazoles
WO2003037351A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
WO2003086287A2 (en) * 2002-04-08 2003-10-23 The Ohio State University Research Foundation Compounds and methods for inducing apoptosis in proliferating cells
WO2004002420A2 (en) 2002-06-28 2004-01-08 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20080003258A1 (en) * 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
US8455458B2 (en) * 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
BRPI0408556A (pt) * 2003-03-20 2006-03-21 Pharmacia Corp formulações dispersìvel de um agente antiinflamatório
AU2004237439B2 (en) 2003-05-07 2009-09-10 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
EP1690852A1 (en) * 2003-12-01 2006-08-16 Reverse Proteomics Research Institute Co., Ltd Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto
WO2005063716A1 (en) 2003-12-22 2005-07-14 Janssen Pharmaceutica, N.V. Imidazoles and their use cck-1 receptor modulators
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
TW200911240A (en) * 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
CN103443092B (zh) * 2011-02-03 2015-11-25 鲁平有限公司 用作α7胆碱受体调节剂的吡咯衍生物
CN103242233B (zh) * 2012-02-08 2014-07-30 北京博爱汇康医药科技有限责任公司 制备塞来昔布的新方法
WO2014012074A2 (en) * 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
RU2019101889A (ru) 2013-03-15 2019-03-28 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
CN105209440B (zh) 2013-03-15 2019-07-23 维颂公司 作为凝血酶抑制剂的卤代吡唑
EP2886104A1 (en) 2013-12-11 2015-06-24 Patir, Suleyman An intra-articular gel
CA2960790A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CN107686465B (zh) * 2017-09-02 2020-10-27 东北农业大学 地拉考昔的制备方法
CN114292235B (zh) * 2021-12-29 2023-04-14 江苏天和制药有限公司 一种地拉考昔的制备和提纯方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
GB8814587D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Condensed pyrazole 3-oxo-propanenitrile derivatives & process for their preparation
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
ATE212985T1 (de) * 1993-11-30 2002-02-15 Searle & Co Tricyclische,substituierte pyrazolyl- benzolsulfonamide und ihre verwendung als cyclooxygenase ii inhibitoren
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders

Also Published As

Publication number Publication date
PL191934B1 (pl) 2006-07-31
KR19990063874A (ko) 1999-07-26
BR9610974A (pt) 1999-07-13
AU718300B2 (en) 2000-04-13
ATE238058T1 (de) 2003-05-15
WO1997011704A1 (en) 1997-04-03
NO981392D0 (no) 1998-03-27
CN1202828A (zh) 1998-12-23
PT854723E (pt) 2003-08-29
IL123635A0 (en) 1998-10-30
PL325952A1 (en) 1998-08-17
AU7376896A (en) 1997-04-17
RO120408B1 (ro) 2006-01-30
DK0854723T3 (da) 2003-08-11
RU2253456C2 (ru) 2005-06-10
CA2233620C (en) 2011-11-22
IL123635A (en) 2003-06-24
CZ297183B6 (cs) 2006-09-13
EP0854723A1 (en) 1998-07-29
NO321157B1 (no) 2006-03-27
KR100498730B1 (ko) 2005-09-09
DE69627683T2 (de) 2003-12-18
DE69627683D1 (de) 2003-05-28
US5756529A (en) 1998-05-26
NZ320919A (en) 1999-10-28
CA2233620A1 (en) 1997-04-03
EP0854723B1 (en) 2003-04-23
CZ89798A3 (cs) 1999-04-14
ES2197954T3 (es) 2004-01-16
JPH11514991A (ja) 1999-12-21

Similar Documents

Publication Publication Date Title
NO981392L (no) Substituerte pyrazolylbenzensulfonamider for anvendelse i veterinµrterapi som antiinflammatorisk middel
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
PT946507E (pt) Compostos de pirrolilo substituidos para o tratamento da inflamacao
PT772600E (pt) Compostos de imidazolilo substituido nas posicoes 1 e 2 para o tratamento da inflamacao
PT923933E (pt) Pirazolil-benzenossulfonamidas substituidas para usar no tratamento de inflamacao
ES2059965T3 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.
MY119711A (en) Method of inhibiting photoaging of skin
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
ES2135703T3 (es) Composicion y procedimiento destinados para prevenir y tratar las inflamaciones con la ayuda de inmunoglobulina.
ATE226014T1 (de) Prophylaktische behandlung der allergischen kontaktdermatitis
PT971694E (pt) Preparacoes de medicamentos para o tratamento de disfuncao sexual
ES2162051T3 (es) Preparacion dermatologica para tratar queratosis actinicas.
CA2339384A1 (en) Improved method for targeted topical treatment of disease
MX9400630A (es) 6-cloro-5-fluoro-3-(2-tenoil)-2-oxindol-1-carboxamida como un agente analgesico y antiinflamatorio.
NO984446L (no) FremgangsmÕte for behandling av smerte
BG101126A (en) The use of muramylpeptide compounds
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
NO950925L (no) Preparat og fremgangsmåte for behandling av hårtap
DE69739482D1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
UA8280A (uk) Спосіб лікування псоріазу
NO981020L (no) Transdermalt terapautisk system for silatranforbindelser
ES2120573T3 (es) 24-epi-1-alfa-hidroxivitamina d2 para tratar la osteoporosis.
UA18225A (uk) Спосіб лікуваhhя раh

Legal Events

Date Code Title Description
MK1K Patent expired